istisociclib   Click here for help

GtoPdb Ligand ID: 13068

Synonyms: compound 28 [PMID: 37967851] | KB-0742 | KB0742
Compound class: Synthetic organic
Comment: KB-0742 is a small molecule CDK9 inhibitor [1-2]. The chemical structure for KB-0742 matches that for the INN istisociclib from WHO proposed INN list 131 (August 2024).
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 5
Hydrogen bond donors 2
Rotatable bonds 5
Topological polar surface area 66.01
Molecular weight 287.4
XLogP 2.48
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CCC(CC)C1=NC2=CC=NN2C(=C1)N[C@H]3CC[C@@H](C3)N
Isomeric SMILES CCC(CC)C1=NC2=CC=NN2C(=C1)N[C@H]3CC[C@@H](C3)N
InChI InChI=1S/C16H25N5/c1-3-11(4-2)14-10-16(19-13-6-5-12(17)9-13)21-15(20-14)7-8-18-21/h7-8,10-13,19H,3-6,9,17H2,1-2H3/t12-,13-/m0/s1
InChI Key VYKCLMALANGCDF-STQMWFEESA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

No information available.
Summary of Clinical Use Click here for help
KB-0742 is proposed as a clinical candidate to treat MYC-dependent cancers.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04718675 A Dose Escalation and Cohort Expansion Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors or Non-Hodgkin Lymphoma Phase 1/Phase 2 Interventional Kronos Bio